GlassScriptPhysician profile
Michael A Geffin
NPI 1578583902
$8,198.88
in general payments reported to CMS, 2019-2025
48 companies · $2,654 in 2025
The $2,654 reported for 2025 was more than what 85% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,810 · 2020: $357 · 2021: $556 · 2022: $727 · 2023: $834 · 2024: $1,262 · 2025: $2,654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,745 · Education: $4.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,744.68 |
| Education | $4.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,532.04 | 2019-2025 | Erleada, Akeega, Carvykti |
| Neotract INC. | $791.58 | 2019-2020 | |
| Astellas Pharma US INC | $461.00 | 2019-2025 | Myrbetriq, Xtandi, Veozah |
| Sumitomo Pharma America, INC. | $373.47 | 2024-2025 | Gemtesa |
| Endo Pharmaceuticals INC. | $351.84 | 2019-2024 | Xiaflex, Aveed |
| Dentsply Ih Ab | $327.50 | 2023-2024 | Lofric, Lofric |
| Dendreon Pharmaceuticals LLC | $319.01 | 2019-2025 | Provenge |
| Ferring Pharmaceuticals INC. | $300.02 | 2019-2025 | Adstiladrin |
| Novartis Pharmaceuticals Corporation | $297.36 | 2022-2025 | |
| Urogen Pharma, INC. | $277.10 | 2021-2025 | Jelmyto |
| Progenics Pharmaceuticals, INC. | $275.62 | 2021-2024 | Pylarify |
| Pfizer INC. | $208.96 | 2019-2023 | |
| Tolmar, INC. | $207.08 | 2023-2025 | Eligard, Jatenzo |
| 180 Medical, INC. | $203.79 | 2019-2025 | Gentlecath, Gentlecath Glide |
| Teleflex LLC | $194.63 | 2022-2025 | Urolift, Barrigel |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Geffin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.